<DOC>
	<DOCNO>NCT02104362</DOCNO>
	<brief_summary>Recently , HDR brachytherapy deliver 19 Gy fraction propose exclusive treatment low intermediate risk prostate cancer . With median 3-year follow-up , Spanish team report biochemical control rate 100 % 87 % , respectively , low risk intermediate risk tumor . In parallel encouraging result regard biochemical control , author describe excellent urinary digestive tolerance , notably absence grade &gt; 2 complication . However , note , study , special protection provide anterior aspect rectum mean 10 ml transperineal injection hyaluronic acid prostate-rectal interspace . The idea use single high dose ( one fraction ) propose MSKCC team Fucks et al . , 2008 , follow median 18-month follow-up , publish 90 % local control rate spinal metastasis single dose 18 24 Gy . The aim present study analyze acute urinary digestive toxicity ( &lt; 180 day ) observe follow interstitial high dose rate prostate brachytherapy deliver total dose 20 Gy one fraction .</brief_summary>
	<brief_title>Single Fraction Early Prostate Irradiation ( SiFEPI )</brief_title>
	<detailed_description>Expected benefit ( ) trial - Improved quality life brachytherapy account absence radioactive seed prostate : - Fewer early urinary complication , - No urine filtration , - No post-operative use condom , - No 2-year ban cremation follow treatment , - Health cost saving , - Acquisition dosimetric data inverse optimization . Predictable risk ( ) patient Predictable risk context trial involve frequency essentially urinary disorder . Methodology Open , monocentric , phase I-II study .</detailed_description>
	<criteria>Patients suffer histologicallyproven adenocarcinomatype prostate cancer : low risk biochemical recurrence low intermediate risk biochemical recurrence ( maximum 1 intermediate risk factor ) * stage T1c , T2a , T2b Gleason score 6 ( 3+3 ) 7 ( 3+4 ) 3 positive biopsy PSA &lt; 15 ng/ml Age ≥ 18 year Karnofsky index ≥ 70 % Life expectancy ≥ 10 year No contraindication injection hyaluronic acid prostaterectal interspace Patient aware information leaflet sign informed consent form Patient cover medical insurance Stage ≥ T2c Gleason score 7 ( 4+3 ) ≥ 8 PSA &gt; 15 ng/ml Presence follow anatomicopathological criterion : Involvement nerve fiber Peritumoral vascular embolism Capsule involvement Number positive biopsy ≥ 50 % 100 % positive biopsy lobe Involvement seminal vesicle Prostate volume ≥60 cc Large prostatic transurethral resection and/or date less 6 month Poor urinary function absence alphablockers IPSS score &gt; 15 Postmictional residue &gt; 50 cc Flow rate Qmax &lt; 12 ml/s Remote metastasis Neoadjuvant antiandrogenic treatment Prior treatment pelvic irradiation and/or chemotherapy Active infection underlie severe pathology likely prevent patient receive treatment History cancer basocellular cutaneous cancer form cancer complete remission 5 year Evolving psychiatric disorder Vulnerable person define article L11215 8</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>